Pilot Study Investigating Brain Natriuretic Peptide, Troponin, Galectin-3, and miRNA-126a-5p as Biomarkers of Persistent Pulmonary Hypertension in Neonates with Hypoxic-Ischemic Injury Receiving Therapeutic Hypothermia

What Was Tested

The paper reports a study of BNP (Nesiritide), published as an observational study.

The objective was to evaluate the utility of brain natriuretic peptide (BNP), troponin, galectin-3 (Gal-3), and microRNA (miRNA)-126a-5p as screening biomarkers for persistent pulmonary hypertension of the newborn (PPHN) by comparing expression in serum of infants with hypoxic-ischemic injury that develop PPHN to those that do not.

Why It Was Studied

· Serum biomarkers of persistent pulmonary hypertension of the newborn. · Serum biomarkers of hypoxic-ischemic injury.

Who Took Part

According to the abstract, 40 patients were involved.

PubMed tags the participants as both men and women.

Serial measurements of biomarkers were performed from 6 to 96 hours post-TH initiation in 40 patients.

How the Study Was Run

The design is described as pilot.

It is described as a pilot, a small early test of whether a larger BNP (Nesiritide) study would be practical.

This was a prospective, observational pilot study including neonates with hypoxic-ischemic injury undergoing therapeutic hypothermia (TH) at two regional perinatal medical centers.

PPHN in this population was diagnosed clinically and confirmed by echocardiogram.

What Was Measured

Topics PubMed links to this paper include Pilot Projects, Natriuretic Peptide, Brain, Biomarkers, MicroRNAs, Hypothermia, Induced, Galectin 3 and Troponin.

What This Means in Plain Language

The paper is a pilot study of BNP (Nesiritide) in 40 patients.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (American journal of perinatology), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.